Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Net Margin: 2013-2025

Historic Net Margin for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to 77.66%.

  • Coherus Oncology's Net Margin fell 53120.00% to 77.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 194.53%, marking a year-over-year increase of 4020.00%. This contributed to the annual value of 10.68% for FY2024, which is 10316.00% up from last year.
  • Latest data reveals that Coherus Oncology reported Net Margin of 77.66% as of Q3 2025, which was down 97.68% from 3,341.42% recorded in Q2 2025.
  • Coherus Oncology's Net Margin's 5-year high stood at 7,405.16% during Q1 2024, with a 5-year trough of -233.47% in Q1 2023.
  • For the 3-year period, Coherus Oncology's Net Margin averaged around 1,032.06%, with its median value being 77.66% (2025).
  • Per our database at Business Quant, Coherus Oncology's Net Margin spiked by 763,863bps in 2024 and then tumbled by 752,584bps in 2025.
  • Coherus Oncology's Net Margin (Quarterly) stood at -62.34% in 2021, then plummeted by 6,747bps to -129.81% in 2022, then skyrocketed by 4,278bps to -87.03% in 2023, then spiked by 16,669bps to 79.66% in 2024, then slumped by 53,120bps to 77.66% in 2025.
  • Its Net Margin was 77.66% in Q3 2025, compared to 3,341.42% in Q2 2025 and -120.69% in Q1 2025.